US Supreme Court Rules on Teva Pharma’s Copaxone Patent Case
Teva Pharmaceutical Industries Ltd. recently made a major announcement on the U.S. Supreme Court‘s ruling on the matter of “Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Courtās judgment of invalidity of Tevaās ā808 patent for COPAXONEĀ®Ā (glatiramer acetate injection) 20 mg/mL.”Ā According to Teva’s report, the Supreme Court has returned the case to the Federal Circuit for supplementary review in light of theĀ applicable standard the Supreme Court laid out for designationĀ review of claim construction.
āWe are encouraged by the U.S. Supreme Courtās Decision and lookĀ forward to the Federal Circuitās review,ā said Erez Vigodman, President and CEO of Teva. āWe will continue to explore all available avenues to protect our intellectual property for COPAXONEĀ®Ā 20mg/mL. COPAXONEĀ®Ā will remain a proprietary, global market leading product for the reduction in the frequency of relapses in patients with relapsing forms of MS over the productās lifecycle.ā
It was last October 15, 2014 when the Supreme Court was presented with oral arguments on theĀ Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. case, meant to decide on whether or not claim construction rulings in patent cases are qualified forĀ deference in the event aĀ local court makes factual findings in the process.
Last year, the Court of Appeals for the Federal Circuit endorsed 4 Teva patents that had expired May 2014, while nullifying a separate ‘808 patent due to expire come September 1, 2015. Before the appellate court passed its ruling, in July 2012 the US District Court for theĀ Southern District of New York supported the Company, and the ‘808 patent for multiple sclerosis drug, CopaxoneĀ® 20mg/mLĀ ā aĀ glatiramer acetate injection for the disease’s relapsing-remitting form.
[adrotate group=”4″]
āThere is currently no FDA-approved follow-on version of Tevaās COPAXONEĀ®,ā saidĀ Rob Koremans, MD, the President and Chief Executive OfficerĀ of Global Specialty Medicines at Teva, āWe are encouraged by the FDAās willingness to date to have dialogue regarding the complexities of COPAXONEĀ®Ā 20 mg/mL and the potential limitations and other unknowns of purported follow-on versions.ā
COPAXONEĀ®Ā is available internationally in its original 20 mg/mL formulation. On January 2014, the Company launched a 40 mg/mL thrice weekly dose in the U.S. Now, the novel MS drug is approved in over 50 countriesĀ including the United States, Russia, Canada, Mexico, Australia, Israel, and in all European countries.